Focus Partners Wealth Purchases 5,337 Shares of McKesson Corporation $MCK

Key Points

• Focus Partners Wealth increased its McKesson stake by 8.5% in Q3, buying 5,337 shares to hold 68,181 shares valued at about $52.7 million (0.06% of the company).
• McKesson beat quarterly estimates with EPS of $9.34 (vs. $9.19) and revenue of $106.16B (up 11.4% YoY), set FY2026 EPS guidance of 38.80–39.20, and carries a consensus "Moderate Buy" with an average target of $960.93.

Focus Partners Wealth increased its position in McKesson Corporation (NYSE:MCK - Free Report) by 8.5% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 68,181 shares of the company's stock after buying an additional 5,337 shares during the quarter. Focus Partners Wealth owned 0.06% of McKesson worth $52,676,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also added to or reduced their stakes in MCK. Brighton Jones LLC grew its holdings in McKesson by 46.3% during the 4th quarter. Brighton Jones LLC now owns 2,523 shares of the company's stock worth $1,438,000 after acquiring an additional 798 shares during the last quarter. Caxton Associates LLP bought a new position in shares of McKesson during the first quarter valued at $233,000. Sivia Capital Partners LLC lifted its holdings in shares of McKesson by 77.9% during the second quarter. Sivia Capital Partners LLC now owns 685 shares of the company's stock worth $502,000 after purchasing an additional 300 shares during the period. Cetera Investment Advisers grew its stake in shares of McKesson by 0.8% in the second quarter. Cetera Investment Advisers now owns 37,812 shares of the company's stock worth $27,708,000 after purchasing an additional 297 shares during the last quarter. Finally, Avantax Advisory Services Inc. increased its holdings in McKesson by 7.6% in the second quarter. Avantax Advisory Services Inc. now owns 4,556 shares of the company's stock valued at $3,339,000 after purchasing an additional 320 shares during the period. 85.07% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the company. Leerink Partners reaffirmed an "outperform" rating and set a $1,085.00 target price on shares of McKesson in a research report on Thursday, March 5th. Wall Street Zen cut McKesson from a "buy" rating to a "hold" rating in a research note on Saturday. Deutsche Bank Aktiengesellschaft restated a "buy" rating on shares of McKesson in a research report on Wednesday, December 10th. Zacks Research lowered McKesson from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, November 25th. Finally, Evercore reissued an "outperform" rating on shares of McKesson in a research report on Thursday, March 5th. Thirteen equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $960.93.

McKesson Trading Up 0.3%

Shares of MCK opened at $943.43 on Tuesday. The firm's fifty day simple moving average is $896.29 and its two-hundred day simple moving average is $828.19. McKesson Corporation has a 12 month low of $637.00 and a 12 month high of $999.00. The stock has a market capitalization of $115.56 billion, a P/E ratio of 27.13, a price-to-earnings-growth ratio of 1.51 and a beta of 0.38.

McKesson (NYSE:MCK - Get Free Report) last announced its quarterly earnings data on Wednesday, February 4th. The company reported $9.34 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $9.19 by $0.15. McKesson had a negative return on equity of 338.97% and a net margin of 1.09%.The company had revenue of $106.16 billion for the quarter, compared to the consensus estimate of $105.98 billion. During the same period in the previous year, the business earned $8.03 EPS. The firm's revenue was up 11.4% compared to the same quarter last year. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. As a group, research analysts predict that McKesson Corporation will post 32.77 EPS for the current fiscal year.

McKesson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 1st. Shareholders of record on Monday, March 2nd will be issued a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date is Monday, March 2nd. McKesson's dividend payout ratio is presently 9.43%.

Insider Activity

In other news, EVP Leann B. Smith sold 190 shares of the firm's stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $945.00, for a total transaction of $179,550.00. Following the completion of the sale, the executive vice president owned 2,989 shares of the company's stock, valued at $2,824,605. This trade represents a 5.98% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP Michele Lau sold 2,725 shares of the business's stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $990.00, for a total transaction of $2,697,750.00. Following the transaction, the executive vice president owned 3,247 shares in the company, valued at $3,214,530. The trade was a 45.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 3,868 shares of company stock worth $3,743,820. Company insiders own 0.08% of the company's stock.

McKesson Profile

McKesson Corporation NYSE: MCK is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company's core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.